Glaucoma surgery devices market is projected to grow from $2.1 billion in 2025 to $4.3 billion by 2035, reflecting a compound annual growth rate (CAGR) of 7.4% over the forecast period of 2026–2035. A key macroeconomic driver underpinning this growth is the escalating global burden of glaucoma. According to the Glaucoma Research Foundation, glaucoma has been identified as one of the leading causes of blindness worldwide, with approximately 80 million people currently affected by the disease. A particularly concerning aspect is that nearly half of all patients remain undiagnosed, largely due to the condition's asymptomatic or "silent" progression in its early stages. 

Gaucher disease treatment market was valued at $2.5 billion in 2025 and is projected to reach $5.3 billion by 2035, registering a CAGR of 7.80% during 2026–2035. The market growth is largely driven by increasing awareness and improved diagnosis rates of rare genetic disorders globally. Advancements in biologics, particularly enzyme replacement therapies (ERTs) and substrate reduction therapies (SRTs), are significantly enhancing treatment outcomes. Rising investments in research and development are further accelerating innovation in targeted therapies. Additionally, supportive government policies and orphan drug incentives are encouraging pharmaceutical companies to expand their product portfolios. Expanding healthcare infrastructure and access to specialized treatments in emerging markets are also contributing to overall market growth.

Fondaparinux market was valued at approximately $778.4 million in 2025 and is projected to reach around $1,459.5 million by 2035, expanding at a CAGR of 6.6% during the forecast period from 2026 to 2035. Market growth is primarily driven by the rising burden of thromboembolic disorders and increasing demand for effective anticoagulant therapies. According to the World Health Organization (WHO), cardiovascular diseases account for nearly 17.9 million casualties annually, with thrombotic events such as deep vein thrombosis (DVT) and pulmonary embolism (PE) being major contributors. This growing disease burden is significantly increasing the adoption of anticoagulants like fondaparinux, particularly in hospital settings for surgical thromboprophylaxis and acute care management.

Fermented ingredients market was valued at $35.2 billion in 2025 and is projected to reach $63.8 billion by 2035, growing at a CAGR of 6.2% during the forecast period (2026–2035). The market is primarily driven by the rising global demand for processed, functional, and value-added food products. According to a July 2025 report by the Organisation for Economic Co-operation and Development and the Food and Agriculture Organization, global agricultural consumption is expected to increase by approximately 13%, while production is projected to grow by 14% over the next decade, supported by strong demand from emerging economies. This upward trend in food and feed consumption is significantly boosting the need for fermentation-derived ingredients. Products such as amino acids, enzymes, and organic acids are increasingly being utilized in food processing and livestock nutrition. As a result, the expansion of agricultural output and food demand is expected to play a crucial role in accelerating market growth.

Enzyme replacement therapy market was valued at $12.0 billion in 2025 and is projected to reach $21.9 billion by 2035, growing at a CAGR of 6.20% during the forecast period (2026–2035). Market growth is driven by the rising prevalence of rare genetic disorders, particularly lysosomal storage diseases (LSDs), and increasing access to specialized treatments. According to the World Health Organization, rare diseases collectively affect over 300 million people globally, creating significant demand for targeted therapies such as enzyme replacement treatments. This growing patient pool, combined with advancements in biologics manufacturing and improved diagnosis rates, is accelerating the adoption of ERT across hospitals and specialty care centers.

Disposable gloves market was valued at $15.5 billion in 2025 and is projected to reach $27.3 billion by 2035, growing at a CAGR of 5.80% during the forecast period (2026–2035). Market growth is primarily driven by increasing healthcare safety standards and infection prevention practices globally. According to the World Health Organization emphasized that, medical gloves are essential for infection prevention but do not replace proper hand hygiene practices. The organization highlighted that improper or excessive glove use can increase contamination risks and contribute to healthcare waste. WHO further noted that nearly 2 in 5 healthcare facilities lack basic hand hygiene services, reinforcing the need for balanced glove usage and hygiene protocols. Additionally, rising industrial safety regulations across manufacturing and food processing sectors are further accelerating adoption.

Dental cement market was valued at $1.0 billion in 2025 and is projected to reach $1.7 billion by 2035, registering a CAGR of 5.80% during the forecast period from 2026 to 2035. Market growth is primarily driven by the increasing prevalence of oral diseases worldwide. According to the World Health Organization, oral diseases affect approximately 3.7 billion people globally, with untreated dental caries being the most common condition. The high cost and limited accessibility of dental care, particularly in low- and middle-income countries, continue to pose significant challenges. This scenario is accelerating the demand for effective and affordable restorative dental solutions, including dental cements. Furthermore, the rising number of dental visits and growing adoption of prosthodontic procedures are supporting market expansion. Increased awareness of oral health and advancements in dental materials are also contributing to sustained growth across both developed and emerging markets.

Corporate assessment service market is expected to expand from $3.8 billion in 2025 to $10.1 billion by 2035, growing at a CAGR of 10.2% during 2026–2035. This growth is primarily driven by the increasing adoption of AI-powered hiring solutions and ongoing digital workforce transformation. In November 2024, the International Telecommunication Union reported that around 5.5 billion people (68% of the global population) were using the internet, marking an increase of 227 million users from 2023. Despite this progress, approximately 2.6 billion people remain offline, highlighting persistent digital disparities. Rising internet penetration is significantly boosting the adoption of digital platforms, including AI-driven recruitment and corporate assessment tools. This trend is accelerating the shift toward remote hiring, online testing, and workforce analytics solutions. As global connectivity continues to improve, it is expected to further enhance the scalability and effectiveness of data-driven talent assessment platforms.

Connected ship market was valued at $5.4 billion in 2025 and is expected to reach $10.1 billion by 2035, expanding at a CAGR of 6.6% during the forecast period from 2026 to 2035. The market is expanding due to the increasing digitalization of maritime operations and the rising need for real-time monitoring and operational efficiency. According to the International Telecommunication Union (ITU), global internet users reached 6 billion people, representing around 75% of the population, with more than 240 million new users added in 2025. Additionally, 5G coverage has expanded to approximately 55% of the global population, reflecting rapid advancements in connectivity infrastructure. This growth in global connectivity is indirectly accelerating the adoption of connected ship technologies, particularly satellite communication systems and IoT-enabled solutions. These technologies enable seamless data exchange, improved navigation, and enhanced fleet management capabilities. Furthermore, the growing emphasis on fuel efficiency, regulatory compliance, and predictive maintenance is driving investments in advanced maritime digital solutions. As a result, connected ship technologies are becoming increasingly essential across global maritime industries.

Companion diagnostics market was valued at $5.5 billion in 2025 and is projected to reach $14.7 billion by 2035, growing at a CAGR of 10.5% from 2026 to 2035. The market is expanding due to the increasing adoption of precision medicine and targeted therapeutic approaches. According to the Personalized Medicine Coalition, its Personalized Medicine at FDA 2024 report highlights that a substantial proportion of newly approved drugs are personalized therapies that rely on biomarker-based testing. In 2024, personalized medicines accounted for nearly 38% of all FDA approvals, reflecting a strong shift toward individualized treatment strategies. This growing dependence on biomarker-driven therapies is significantly increasing the demand for companion diagnostics. Additionally, the rising use of next-generation sequencing (NGS) technologies is enhancing the accuracy of disease detection and treatment selection. These advancements are improving clinical outcomes while supporting broader adoption of precision diagnostics across healthcare systems.